On May 5, 2021 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, reported that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 after the close of the U.S. financial markets (Press release, Prothena, MAY 5, 2021, View Source [SID1234579220]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 11.

On May 5, 2021 BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undruggable targets, reported that it has raised $12 million in a Series A private financing round led by Wedo Venture Partners with additional participation by Kaitai Capital and Takeda Ventures, alongside existing investor Pangu Venture (Press release, Bridgene Biosciences, MAY 5, 2021, View Source [SID1234579237]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BridGene plans to use proceeds from the Series A financing to expand the company’s proprietary covalent library to discover small-molecule ligands for a broader range of targets, advance existing oncology programs and enhance operations.

The Company’s proprietary chemoproteomic platform, IMTAC (Isobaric Mass Tagged Affinity Characterization), addresses many of the challenges associated with small-molecule drug discovery. Many disease drivers have long been deemed undruggable because their functional pockets are either too shallow or formed transiently in live cells, making such conditions difficult for conventional small molecules to address. While phenotypic screening can be performed in live cells, it is extremely difficult to identify small-molecule hits’ cellular targets that are responsible for the phenotypic modulation. BridGene has the unique ability to meet these challenges as IMTAC screening not only enables the efficient discovery of novel hits for myriad proteins, including those deemed undruggable in live cells, but also allows target deconvolution for phenotypic screening hits.

"We are pleased to make this investment, as we believe BridGene plays an important role in discovering small molecules for traditionally undruggable targets, as well as rapidly identifying (deconvoluting) targets in phenotypic screening, and revolutionarily developing precision medicine for a wide range of unmet medical need," said Leilei Wang, managing partner of Wedo Venture Partners. "Medical advancement requires greater efficiency across the spectrum of development – from discovery through commercialization, and BridGene’s IMTAC platform has the potential to positively impact the earliest, and often most challenging, steps in this process."

"This financing, combined with our recently announced collaboration with Takeda, affirms the strong support among investors and pharmaceutical developers for our proprietary drug discovery and development platform and experienced management team," stated Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences. "Over the last few years, we have pursued pioneering work in covalent small molecules and chemoproteomic screening to identify small molecules for traditional undruggable targets and quickly move from hits to leads. Today, thanks to the help of our investors, we are in a strong financial position to continue building a unique chemoproteomic platform and advance the development of our internal pipeline with the goal of providing new therapies for unmet medical needs."

On May 5, 2021 MannKind Corporation (Nasdaq:MNKD) reported that it will release its 2021 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 12, 2021 (Press release, Mannkind, MAY 5, 2021, View Source [SID1234579152]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company’s website at View Source under Events & Presentations. A replay will also be available on MannKind’s website for 14 days.

On May 5, 2021 Oncopeptides, a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, reported that the Company has completed patient enrollment in the phase 2 PORT study (Press release, Oncopeptides, MAY 5, 2021, View Source [SID1234646796]). The PORT study is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma. Oncopeptides expects topline data in Q3 2021.
"I am very pleased that we have enrolled the final patient in the PORT study," said Klaas Bakker, MD, PhD and Chief Medical Officer at Oncopeptides. "The data could potentially provide a pathway for us to work with the U.S. Food and Drug Administration to include an additional mode of administration for PEPAXTO."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The continued development of melphalan flufenamide could potentially bring forward an additional therapeutic option to physicians and patients," said Joshua Richter, MD, Assistant Professor of Medicine, Hematology and Medical Oncology at The Tisch Cancer Institute at Mount Sinai and Site Director of Multiple Myeloma at the Blavatnik Family – Chelsea Medical Center at Mount Sinai, New York.

On May 4, 2021 iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, reported that it has successfully resolved its lawsuit with Fraunhofer USA, Inc. ("Fraunhofer USA") (Press release, iBioPharma, MAY 4, 2021, View Source [SID1234585482]). The parties’ settlement confirms iBio’s ownership of certain intellectual property related to plant-based biopharmaceutical production. As part of the settlement, iBio granted Fraunhofer USA a fully paid-up license to use the recombinant protein manufacturing technologies that were the subject of litigation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tom Isett, Chairman and CEO of iBio, said, "We are pleased to see this matter resolved and to receive compensation for the use our intellectual property. iBio remains committed to relentlessly innovating in the area of plant-made biologics, while respecting fair competition and protecting our IP. As a result, this settlement gives assurance to our licensees and clients that they can continue to depend upon us to develop and enhance our FastPharming Technologies to provide them with the speed, scalability, and eco-friendly advantages of plant-based biologics development and manufacturing from iBio."

The Settlement concludes the lawsuit that began in March 2015 in the Delaware Court of Chancery. In addition to an initial payment at signing which will cover iBio’s significant legal fees and expenses, Fraunhofer USA will make additional cash payments to iBio in March 2022 and March 2023. Certain details of the settlement are confidential.